Introduction
Molecular biology is providing powerful new insights and techniques which might have therapeutic benefits for problems affecting the brain. The techniques for applying these in clinical settings still require extensive study to demonstrate the ability to insert functional genes into appropriate cellular targets and to demonstrate their function during a useful period of time. One possible target for such approaches is Parkinson's disease (PD), which is characterized by tremors, rigidity and akinesia secondary to the progressive degeneration of the dopamine neurons of the substantia nigra. The dopamine depletion within the projection area of the caudateputamen has provided the rationale for current pharmacological treatments which act to facilitate brain dopami-nergic transmission. L-Dopa is the current mainstay of treatment and is clearly efficacious at first. However, as the disease progresses, patients become increasingly refractory to this and related drug treatments. In view of the significant morbidity and mortality associated with advanced, drug-refractory PD, several experimental strategies have been investigated. Perhaps the most promising replacement strategy is the intrastriatal transplantation of fetal mesencephalic cells. Although transplantation has met with some clinical success, [1] [2] [3] its use has been limited in part due to difficulty in obtaining adequate quantities of safe and viable fetal cells. Host rejection of non-matched human or animal tissues or cell lines has not been eliminated as a major potential problem. A complementary approach might be the insertion of therapeutic genes into cells which are then implanted into the brain or the direct insertion of genes into the brain. Previous reports in rodents have shown efficacy in dopamine-depletion models in which the therapeutic gene tyrosine hydroxylase (TH), the rate-limiting enzyme in dopamine biosynthesis, is stably introduced into cells ex vivo. These engineered cells are then implanted into 821 the denervated striatum. 4, 5 Unfortunately, transplanted cells may be targets of possible disease-specific degenerative processes, immune rejection, or in the case of some cell sources may have uncontrolled replication capability. Futhermore, the cells may disturb the host circuitry in the vicinity of the implant. An alternative approach is that of direct in vivo gene therapy which may provide advantages over ex vivo therapy. In this approach, normal cells in the brain of the host are the targets for the induced production of neurotransmitters or growth factors. However, it is more difficult to deliver gene products to nondividing neurons which might be the appropriate targets for increasing neurotransmitter production. We and others have previously used herpes simplex virus type I (HSV-1) 6 and adenoviral vectors, 7 to introduce the human TH gene into cells of the denervated striatum after 6-hydroxydopamine-induced dopamine depletion in the rat. Because of the inherent toxicity of current generation HSV, adenoviral, or HIV-derived vectors, [6] [7] [8] we chose to use an AAV vector in the present study. This vector can be generated free of any helper virus, without viral genes, and with just the minimal elements for packaging and DNA replication (the 145 base inverted terminal repeats). We planned to determine whether AAV vectors could be used in the primate brain and result in long-term expression and biochemical effects after a preliminary study in the rat 9 showed promising results.
Previous studies have shown that the cleavage of the regulatory N-terminal of the TH enzyme results in approximately a 2.5-fold greater enzymatic activity. 10 We therefore constructed a vector with an N-terminal deletion and epitope-tagged (FLAG) to allow endogenous and vector-encoded TH to be distinguished histochemically. Furthermore, although TH catalyzes the conversion of tyrosine to L-Dopa, another enzyme, aromatic amino acid decarboxylase (AADC) is necessary for the decarboxylation of L-Dopa to dopamine. In the parkinsonian striatum, levels of AADC are also depleted and may be limiting for the efficient production of dopamine from L-Dopa. 11 Since the AAV vector system is constrained to packaging of only 5 kb, precluding the use of two complete transcription units, we constructed a bicistronic vector using the encephalomyocarditis internal ribosome entry site (IRES) sequence to generate pAAVflag⌬thIRESaadc ( Figure 1 ). Recombinant AAVflag ⌬thIRESaadc vector was generated using a helper-free packaging system. 12 
Results
Characterization of the vector in vitro Following transfection with AAVflag⌬thIRESaadc, 293 cells were analyzed for production of dopamine ( Figure  1c) .
Furthermore, in a parallel experiment, AAVflag⌬thIRESaadc was compared with AAVflag⌬th, the truncated TH without AADC. This latter construct resulted in high levels of L-Dopa secretion (8200 pg/h/10 6 cells) but no detectable dopamine. In contrast, the bicistronic construct released both L-Dopa (800 pg/h/10 6 cells) and dopamine (4050 pg/h/10 6 cells) into the medium, measured as previously described. 13 In AAVflag⌬thIRESaadc-transfected but not mock-transfected or AAVlac-transfected cells, numerous FLAG-IR cells were detected using immunocytochemistry with a FLAG antibody (Figure 1) . In vivo studies in primates provide means to study vector and gene expression directly in model systems that closely resemble clinical Parkinson's disease. We therefore proceeded to the use of AAVflag⌬thIRESaadc in MPTP-dopamine depleted primates to determine whether this strategy might be effective for transducing primate neurons in the striatum to produce dopamine.
Gene transfer in asymptomatic MPTP-treated subjects A total of 12 adult male St Kitts green monkeys (Cercopithecus aethiops sabaeus) were studied in two experiments. The first experiment, using six St Kitts green monkeys, was aimed to determine safety and efficacy of gene transfer. These monkeys had been systemically treated with MPTP 1-3 years previously, resulting in partial dopamine lesions without significant motor or behavioral impairment.
14 AAVflag⌬thIRESaadc was stereotactically injected unilaterally in three drops into the partially denervated caudate. Following the injection, animals were observed daily for any adverse effects, and no behavioral toxicity was apparent. Two animals were killed at 9 days, two were killed at 73 days, and two survived until killed at 134 days. Following death, brain removal and sectioning, punches were taken for biochemical measurements. 15 Remaining tissue was postfixed for immunocytochemical analysis. 16 One monkey in this group demonstrated a greater than two-fold elevation of tissue dopamine concentration in a punch that could be visualized as in the vicinity of the injection site, compared with the equivalent region on the other side of the brain. Immunocytochemistry revealed the presence of FLAG-IR cells surrounding the injection sites. Moreover, these cells were present both in the 9 day survival animals as well as the 73 and 134 day survival groups, although the immunoreactivity of cells was reduced at later time-points. Histologically, the only evidence of injury was related to the needle-track and a small area around the injection tip.
Gene transfer in parkinsonian MPTP-treated monkeys
In view of the apparent lack of toxicity or ill effects and preliminary evidence suggesting increases in dopamine production, we proceeded to a second study of six monkeys which were significantly behaviorally impaired with tremors, rigidity and severe akinesia. Such animals are known from previous studies 17 to have a more marked and consistent depletion of levels of striatal dopamine than asymptomatic MPTP-treated monkeys. These animals were randomly assigned to receive either AAVflag⌬thIRESaadc or AAVlac 4 months after treatment with MPTP. The vectors were stereotactically implanted bilaterally in three sites, 2 mm apart, in the caudate nucleus on each side of the brain, and animals were studied for 2.5 months. Two animals that received AAVflag⌬thIRESaadc and one that received AAVlac treatments showed transient body temperature elevations up to 40°C, with an onset approximately 7 days after surgery and persisting for about 7 days. No animals showed any other apparent sign of illness. In the immediate postoperative period, one AAVflag⌬thIRESaadc monkey showed evidence of motor hyperactivity and orienting to non-apparent visual or auditory stimuli for a few hours, similar to the syndrome produced by dopamine agonists in high doses. This animal also had an elevated temperature, and was killed after 7 days to investigate potential correlates of these behavioral and physiologic effects.
All three remaining severely parkinsonian monkeys treated with AAVflag⌬thIRESaadc showed evidence of behavioral improvement, based upon both their 'parkinson's rating scores' and systematic analysis of videotapes, compared with their own baselines before treatment. From a condition of severe motor impairment requiring assisted feeding, two monkeys improved to be able to ambulate and eat on their own, although they continued to show significant signs of parkinsonism, including tremor and bradykinesia. The other highly symptomatic AAVflag⌬thIRESaadc-treated monkey showed similar quantitative change but at the end of the study was still more impaired than the other two. One AAVlac-treated monkey showed no change while the other showed behavioral improvement. However, statistical analysis failed to demonstrate any significant differences between the treatment groups after the vector treatments.
Post-mortem assessment of gene transfer After 2.5 months, animals were killed for collection of samples for immunohistochemistry, biochemical determinations of dopamine levels, and PCR. Analysis of the monkeys included PCR analysis of tissues obtained from several brain areas and other tissues to evaluate whether there was viral spread from the injection sites based on the presence of vector DNA. In the one animal in which both mRNA and DNA were isolated from a site close to the injection (T406) both PCR and RT-PCR amplified products were obtained (Figure 2 ). In contrast, in all peripheral tissues and sites more than a few millimeters away from the injection tracks in the brain as well as in the AAVlac-treated controls there were no positive signals, confirming the absence of vector spread. Moreover, we were unable to detect any wild-type AAV using PCR. There were no histological changes suggesting injury or inflammation in the animal that was killed at 7 days, but there was clear TH antibody labeling of cells near the injection tracts (Figure 3a and b) . No obvious inflamma- tory cell infiltration was observed in any of the other monkeys, and immunohistochemistry appeared to show the FLAG epitope in areas near the injections in other MPTP-treated monkeys (Figure 3c and d) . To control for the initial level of dopamine depletion in the biochemical analyses, these monkeys were compared with four MPTP-treated monkeys that received no other treatments and that were chosen based on comparable dopamine depletion in areas away from the implant target regions. In the two monkeys that received AAVlac, tissue dopamine was low throughout the caudate and specifically in the punches adjacent to the injection site. In contrast, in two monkeys that received AAVflag⌬thIRESaadc and also showed the most complete behavioral recovery, the tissue dopamine concentrations were elevated in the sites adjacent to the injection (Figure 4 ). These same two animals also had evidence of sprouting of dopaminergic terminals. Furthermore, numerous FLAG-IR cells were apparent around the injection area. One severely impaired animal treated with AAVflag⌬thIRESaadc, that did not show an increase in DA levels (Figure 4) , showed evidence of a few FLAG-IR cells. 
Figure 3 Immunochemistry for tyrosine hydroxylase (a) reveals the presence of numerous cells with multiple short processes which appear similar to medium spiny neurons of the striatum. These cells are adjacent to the implantation site and were present on several consecutive sections in a monkey (T406) that was killed at 7 days after implantation. They were not seen in more distant regions of the caudate nucleus and appeared to be restricted to within a few millimeters of the implantation site. The higher power view in (b) reveals neuritic extensions from tyrosine hydroxylase positive cells (arrows) as depicted in (a). Staining with antibody to the FLAG epitope, which is selective for the vectored gene AAVthIRESaadc construct, reveals a similar group of labeled cells studied at 73 days after injection of the vectors in another monkey (T801) in the region of the injection tract (c), but not in the cortex or other areas away from the tracks in the injected caudate. A higher power view in (d) reveals neuritic extensions from the cells depicted in (c). Tyrosine hydroxylase antibody shown in (a) and (b), which is not selective for the vector-derived construct, did not label cells in the same regions in the monkeys killed at 73, 74 or 134 days after treatments (a, c × 140; b × 270; d × 350).

Discussion
In this study we demonstrate that AAV can be used as a vector to deliver genes to nondividing neurons of the primate caudate nucleus. Expression was most striking at the earliest time-periods, but persisted over the periods studied. Furthermore, there was no evidence of viral spread or replication, nor was there any evidence for toxicity at the site of injection or elsewhere. One adverse effect was that of a transient fever in several animals. The mechanisms for this fever are not clear, but may have been related to the specific vector stock or possible lowlevel contamination with adenovirus. Only one monkey exhibited abnormal behavioral signs which may have been secondary to a hyperdopaminergic syndrome. Treatment with AAVflag⌬thIRESaadc resulted in partial phenotypic correction of the dopamine deficit in two of three severely parkinsonian monkeys, whereas no dopamine elevations were seen after AAVlac or with no treatment. Unfortunately, since the post-mortem assessments of dopamine do not permit a 'before and after' analysis, these techniques cannot absolutely eliminate the possibility that both the behavioral effects and increases in dopamine were influenced by sprouting of host neurons, which was observed most impressively in the two monkeys showing the greatest biochemical changes and not in the others. Furthermore, given the relatively small number of neurons that seem to be transfected, the biochemical effects were larger than anticipated. These effects might alternatively be related to the high nonregulated activity of the introduced TH and are consistent with previous reports of phenotypic recovery in rodent models of Parkinson's disease in which limited numbers of striatal cells were transduced. 6, 9 Significant improvements in this potential gene therapy approach might be obtained by using multiple injection sites, more optimal volumes, titers and perfusion rates of the vectors, and targeting the putamen in addition to the caudate. Previous studies suggest that relatively small increases in DA function may produce major improvements or even restoration of normal motor function, suggesting that Parkinson's disease, unlike many other gene therapy applications, may be treated successfully even with transduction of only a small population of the 'right' cells. Among the available viral vectors, AAV may be an attractive choice for clinical CNS gene transfer as it has minimal toxicity compared with either HSV or adenoviral vectors. Comparison of this approach with other vector delivery systems in primates will be a critical step toward the realization of new therapeutic approaches in patients.
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Figure 4 Dopamine concentrations near the injection tracts (ventromedial (VM) ) caudate were analyzed and compared with the concentrations at a greater distance (dorsolateral caudate (DL) ) in the animals after death 2.5 months after injection with the constructs containing ␤-galactosidase or TH/aadc. The dorsolateral region reflects the depletion induced by MPTP and may provide an index of the extent of depletion of each animal before treatment. For comparison, four MPTP-treated monkeys that did
Materials and methods
Preparation of viral vectors
Preparations of rAAV vector were made by cotransfection methods according to published protocols 18, 19 with modifications. Briefly, 1-2 h before transfection, 20 15-cm dishes of human 293 cells of 80% confluency were fed with 25 ml fresh IMDM medium (GIBCO, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA) without antibiotics. Fifty 5 g of plasmid DNA (25 5 g packaging plasmid pAAV/Ad 12 plus 25 5 g of vector plasmid, either pdx31-LacZ 18 or AAV-TH-AADC) was dissolved in 2 ml of 0.25 m CaCl 2 and then quickly mixed with 2 ml of HBS buffer (50 mm HEPES, 280 mm NaCl and 1.5 mm Na 2 HPO 4 , pH 7.12). The slightly cloudy mixture was added to the cells. The medium was replaced after 8-12 h transfection with fresh DMEM (GIBCO) medium containing 10% FBS. Adenovirus 5 (dl309) was added to the cells at 2 multiplicity of infection (MOI). After 2. days post-Ad infection, the cells were harvested by low speed centrifugation, resuspended in lysis buffer (10 mm Tris-Cl, pH 8.5, 150 mm NaCl), frozen and thawed four times. Cell debris was removed by low speed centrifugation. To the supernatant, an equal volume of ice-cold saturated (NH4) 2 SO 4 (pH 7.0) was added and placed on ice for 20 min. The sample was then centrifuged at 15 000 g for 10 min. The pellet was redissolved in CsCl-PBS solution (pH 7.5, density 1.38 g/ml) and centrifuged in SW41 rotor (Beckman, Columbia, MD, USA) at 19 000 g for 48 h with 0.5 ml CsCl-PBS cushion (pH 7.5, density 1.5 g/ml). The AAV band was collected and dialyzed against DMEM and heated at 56°C for 30 min.
The AAV-LacZ virus titers were determined by infecting 293 cells at various dilution with 1 MOI of Ad5 (dl309). The cells were fixed 24 h after infection, stained with X-gal. 20 Each blue cell was accounted as infected by one transducing unit of AAV-LacZ virus. The titer of AAV-TH-AADC was determined by vector infectious center (also named replication center) assay. 21, 22 Briefly, various dilutions of AAV-TH-AADC virus stock were used to infect 293 cells seeded in six-well plates (80% confluency). The cells were also simultaneously infected with 10 MOI of Ad5 (dl309) and 5 MOI of wild-type AAV2 for 1 h, followed by change of culture media. At 24 h after infection, the cells were trypsinized and suspended in 10 ml of PBS. One milliliter of the cell suspension was applied to prewetted 47-mm nylon membrane disks (NEN DuPont, Boston, MA, USA) followed by gentle vacuum suction. The disks were treated for 5 min with 0.5 n NaOH, neutralized by 1 m Tris-Cl (pH 7.0) (both solutions were soaked on to Whatman, Clifton, NJ, USA, filter paper), and dried at 65°C. Southern hybridization was performed using TH-AADC DNA as the probe to detect the cells, which had been infected by the rAAV vector and had the vector DNA amplified by the wildtype AAV2 and Ad5. After exposure against radiographic film, each dot on the autoradiograph represented a vector-infected cell, and therefore was translated into one infectious unit of AAV-TH-AADC virus.
Embryonic kidney cell-line methods Kidney 293 cells were transfected by either AAVth, AAVthIRESaadc, AAVlac or mock-transfected. Twenty-four hours following transfection, the medium was replaced with a release buffer (135 mm NaCl, 3 mm KCl, 1.2 mm CaCl 2 , 1.0 mm MgCl 2 , 10 mm glucose, 200 m ascorbate and 2 mm sodium mono-and di-basic phosphate buffered to pH 7.4). Samples of the medium were taken at both 30 min and 60 min and catecholamines analyzed using a coulometric electrode array series HPLC as previously described. 13 
Subjects and treatments
The monkeys were treated with MPTP HCl (RBI, Natick, MA, USA; 0.5 mg/kg i.m. five times over 5 days). Care and treatment of these monkeys were in compliance with the US Public Health Service Guide for the Care and Use of Animals (1985) , and the protocols were approved by the institutional review committees of Yale University School of Medicine and the St Kitts Biomedical Research Foundation. The animals were carefully monitored for health status, food and water intake, and were supplemented with special care and feeding as necessary to maintain adequate intake. 14, 17, 23 Infusion of vector into striatum Fifteen microliters of the AAV vector (titer 10 7 /ml transducing units) were injected through a 22-gauge needle into each of three sites in the monkey caudate using coordinates and injection parameters previously described for implantation of fetal tissue using stereotactic surgery. 23 The flow rate was approximately 1 l/min.
Biochemical and morphological analyses
Tissue micropunches were taken from coronal brain slices and were assayed for dopamine and homovanillic acid concentration as described previously. 15 The remainder of the brain slice was immersion fixed and analyzed for TH immunohistochemistry 16 or was frozen to be later processed by PCR.
Behavioral measures
Twice daily, 5 days per week, subjects were examined and assessments made by 'blinded' observers who scored individual spontaneous and elicited behaviors to assess parkinsonian behavior during the course of the study. 17 A 'parkinsonian summary score,' derived from a principal component factor analysis, was constructed from the observations and used for analysis. Once a week representative samples of behavioral function of each monkey were also videotaped and later analyzed using the same behavioral methods.
PCR analyses DNA was prepared from selected tissues by extraction in proteinase K buffer exactly as described. 6 Recovered DNA was normalized with radiolabelled primers followed by analysis with a phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). In order to simultaneously normalize DNA and determine whether AAVth sequences were present, primers were chosen within the single copy human TH cDNA sequence which flanked a 96 bp intron between exons 4 and 5. 24 These primers were able to amplify a similar sized fragment when using African green monkey DNA as a template. The identity of this band was subsequently verified by cycle sequencing (not shown). One hundred nanograms of normalized DNA together with 5 pmol primers were amplified in a total volume of 50 l. Primers were derived from the human TH cDNA 25 and included nucleotides 519 to 543 (5Ј TCCCCTGGTTCCCAAGA AAAGTGTC) and complementary to nucleotides 639 to 668 (5Ј GGAAGCTGATTGCTGAGATCGCCTTCCAGT). DNA was processed for 40 cycles at 94°C for 0.5 min, at 56°C for 1 min and at 72°C for 0.5 min. Samples were electrophoretically separated on a 5% polyacrylamide gel. Normalized samples were also tested for the presence of wild-type AAV. Oligonucleotides were derived from Srivastava et al 26 and included nucleotides 1887 to 1902 (5Ј TCGATCAACTACGCAG) and complementary to nucleotides 2553 to 2566 (CGCCTGGAACAGTG). DNA was processed for 40 cycles at 94°C for 2 min, 38°C for 1 min and 72°C for 2 min.
RT-PCR
Prior to DNA preparation, approximately half of the selected tissues were used to make total RNA as described. 24 RNA was DNase treated and normalized. 6 One hundred and fifty nanograms were used as a template for first-strand cDNA synthesis with and without reverse transcriptase using a gene-specific primer derived from the SV40 polyadenylation region. The SV40 oligonucleotide was complementary to nucleotides 2574 to 2592 27 (5Ј CACTGCATTCTAGTTGTGG). Second-strand synthesis and further amplification were performed using a radiolabeled primer derived from the human AADC sequence -nucleotides 1177 to 1194; 28 (5Ј GGAGTCAAAAGGACTGCAG). The PCR reaction used 250 ng of cDNA in a total volume of 50 l. DNA was processed for 35 cycles at 94°C for 1.5 min, at 50°C for 1 min, and at 70°C for 1.5 min. To ensure specificity following size separation further, the products were transferred to nylon membranes and probed with a radiolabeled internal oligonucleotide (AADC nucleotides 1516 to 1535; 5Ј TGAAGCCAGCTGCAGGAATC). All analyses were conducted without knowledge of which injections were made in each animal.
